Pulling SEC filings + quote and writing the call…

Generate Biomedicines, Inc.
Next earnings ≈ Aug 6, 2026 · est. from filing cadence
Last earnings -11.2% on 2026-05-07
Mixed signals in the latest filings.
Generate Biomedicines, Inc. shows limited reported revenue.
Sources: SEC EDGAR (CIK 0002100782, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 1:54:29 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1071 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
| 2026-03-04 | Nally Michael Chief Executive Officer | Buy | 20.0K @ $12.00 | $240K |
| 2026-03-02 | Grous Beth Chief People Officer | Buy | 300.00 @ $16.00 | $4.80K |
| 2026-03-02 | Silvers Jason President & CFO | Buy | 500.00 @ $16.00 | $8.00K |
| 2026-03-02 | Silvers Jason President & CFO | Buy | 500.00 @ $16.00 | $8.00K |
| 2026-03-02 | Silvers Jason President & CFO | Buy | 1.00K @ $16.00 | $16.0K |